Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
83.61
+0.57 (+0.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gilead Sciences
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
3 Stocks That Can Help You to Get Richer in 2024 and Beyond
July 25, 2024
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well.
Via
The Motley Fool
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price
July 24, 2024
Gilead Sciences' lenacapavir, marketed as Sunlenca, is under scrutiny for its $42,250 annual price despite research suggesting it could be produced for $40. Campaigners are urging for global price...
Via
Benzinga
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
July 24, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial
July 23, 2024
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient...
Via
Benzinga
Breaking Down Gilead Sciences: 10 Analysts Share Their Views
July 22, 2024
Via
Benzinga
Check Out What Whales Are Doing With GILD
July 19, 2024
Via
Benzinga
Gilead Sciences's Options Frenzy: What You Need to Know
July 11, 2024
Via
Benzinga
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
July 22, 2024
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline.
Via
Benzinga
Biotech Bull Market Is Intact But SMIDs Are Too Volatile
July 22, 2024
It was another wild week for the market as it had to contend with a lot of news.
Via
Talk Markets
Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
July 22, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
This Hidden Gem Vanguard ETF Is Chock-Full of Magnificent Stocks. Here's Why It's a Buy Now.
July 21, 2024
This fund has a basket of growth, income, and value stocks.
Via
The Motley Fool
Topics
ETFs
Looking Into Gilead Sciences's Recent Short Interest
July 10, 2024
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $8,400 Today
July 09, 2024
Via
Benzinga
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
July 19, 2024
Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.
Via
InvestorPlace
Chief Medical Officer Merdad Parsey to Leave Gilead Early 2025
July 17, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
Want $3,000 In Passive Income? Invest $51,000 in These 3 High-Yield Dividend Plays
July 17, 2024
These three dividend vehicles could provide reliable passive income.
Via
The Motley Fool
Gilead to Highlight Landmark Progress in Research Across HIV Prevention, Treatment and Cure Programs at AIDS 2024
July 16, 2024
From
Gilead Sciences, Inc.
Via
Business Wire
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
July 15, 2024
Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market.
Via
InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
3 Dividend Growth Stocks to Buy and Hold
July 14, 2024
What's better than a dividend? A dividend that's growing.
Via
The Motley Fool
Is Iovance Biotherapeutics a Millionaire Maker?
July 14, 2024
This biotech's future is bright, but how good could it get for investors?
Via
The Motley Fool
The 7 Most Undervalued Healthcare Stocks to Buy in July 2024
July 13, 2024
Explore undervalued healthcare stocks offering growth potential and stability in contrast to overvalued tech sector.
Via
InvestorPlace
3 Underappreciated Stocks About to Break Their Chains
July 11, 2024
Explore these underappreciated stocks ready for growth and get an in-depth analysis, forecasts, and news on these potential breakout stocks.
Via
InvestorPlace
Oil Declines Amid Prospects Of An Agreement Between Israel And Hamas. Powell Will Address The Us Congress Today
July 09, 2024
On Monday, the Dow Jones (US30) decreased by 0.08%, while the S&P 500 (US500) added 0.10%. The NASDAQ Technology Index (US100) closed positive 0.28%.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
While the broader healthcare sector enjoys permanent relevance, you can potentially maximize your upside with cheap biotech stocks.
Via
InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
July 08, 2024
Healthcare stocks continue to lag the market up about 6% YTD, helped by Large Cap Biopharma but hurt by United Health.
Via
Talk Markets
This Domino's Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
July 08, 2024
Via
Benzinga
Amgen, Inc. Dividend Stock Analysis
July 05, 2024
Amgen Inc. is one of the world's leading biotech companies with major treatments for anemia, neutropenia, rheumatoid and psoriatic arthritis, psoriasis, cancer and osteoporosis.
Via
Talk Markets
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
July 04, 2024
Biotech stocks are on the verge of a comeback after a period of underperformance amid a wave of FDA approvals.
Via
InvestorPlace
Exposures
Product Safety
3 Undervalued Biotech Gems With 200%+ Analyst Price Targets
July 04, 2024
These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.
Via
InvestorPlace
< Previous
1
2
3
4
5
6
7
8
9
...
50
51
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.